Vimarsana
Biggest News Aggregation in the World

Page 30 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer - Vimarsana News

BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer

09.08.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global ... Seite 1

BeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average […]

BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC - Vimarsana News

BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC

FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period BeiGene (NASDAQ: BGNE; HKEX: 06160

FDA delay means BeiGene, Novartis must wait longer for cancer drug decision - Vimarsana News

FDA delay means BeiGene, Novartis must wait longer for cancer drug decision

The FDA has deferred a regulatory decision on an esophageal cancer drug from partners BeiGene and Novartis, citing the need to complete inspections of the China-based facilities where the drug is made. The agency said Covid-19 travel restrictions have prevented it from conducting those inspections.

BeiGene Appoints Chan Lee as General Counsel - Vimarsana News

BeiGene Appoints Chan Lee as General Counsel

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and